Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06272942 · ClinicalTrials.gov registry record
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
A clinical trial of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS), sponsored by Bayer.
- Active
- Registry status
- 140,000
- Enrollment target
- 1
- Study location
NCT06272942 is a study of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS) that is active but no longer recruiting, run by Bayer. The registered enrollment target is 140,000 participants, above the 235-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (59474% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06272942, a study of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS), is active but no longer recruiting, sponsored by Bayer.
- ACTIVE NOT RECRUITING
- Registry status
- 140,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied. ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult. In observational studies, only observations are made without participants receiving any advice or any changes to health care. People who are admitted to ICU for serious illnesses, like ARDS, often experience new health problems during and after their ICU stays. These health problems that may include physical, mental, and/or emotional disorders, are called post-intensive care syndrome (PICS). Identifying these new health problems early can help people by timely treatments and care. In this study, researchers want to identify any health problems that arise after ICU admission in people with ARDS in the United States (US). To do this, researchers will collect information on health problems, treatments, medicines, and healthcare visits in people with ARDS, 1 year before and after an ICU admission. They will then look to see whether the health problems are in areas that have been described as the post intensive care syndrome (PICS). In addition, they will measure healthcare related costs in the one year after admission and compare it to the one year prior to admission. Researchers will also compare this information with data collected for people with pneumonia who did not require ICU admission. This will help them to identify any new health problems arising due to ICU stays. The data will come from participants' medical claims information stored in the Optum Clinformatics Data Mart database from 2016 to 2022. The claims data will only be collected for people in the US. Researchers will collect data from participants admitted to ICU for ARDS for a maximum of 1 year before and after their stay.
Conditions Studied
Interventions
- OTHER An ICU admission and a temporally related ARDS diagnosis
Study Locations (1)
New Jersey
- Bayer - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140,000 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2025-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06272942
The ClinicalTrials.gov registry entry for NCT06272942 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 140,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (59474% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Respiratory Distress Syndrome (ARDS) appearing as the primary indexed condition, and to 1 intervention - of which An ICU admission and a temporally related ARDS diagnosis is the first listed.
NCT06272942 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06272942 about?
NCT06272942 is a clinical study titled "An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States". This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied. ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult. In observational s...
What is the current status of trial NCT06272942?
This trial is currently active not recruiting. The enrollment target is 140,000 participants. The study started on 2024-01-31. Estimated completion is 2025-08-30.
What conditions does trial NCT06272942 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS).
What interventions are being tested in trial NCT06272942?
The interventions under investigation include: An ICU admission and a temporally related ARDS diagnosis (OTHER).
Who is sponsoring clinical trial NCT06272942?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06272942 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome (ARDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
-
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Acute Respiratory Distress Syndrome (ARDS)
All registered trials for this condition
Post Intensive Care Syndrome (PICS)
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.